Insulet’s Strong Growth and Strategic Expansion Under New Leadership

Analyst Patrick Wood of Morgan Stanley maintained a Buy rating on Insulet (PODD – Research Report), retaining the price target of $325.00.

Patrick Wood has given his Buy rating due to a combination of factors that highlight Insulet’s strong performance and growth potential. The company has shown impressive growth in both the US and international markets, with a notable increase in new customer starts and a significant rise in Type 2 diabetes adoption. This growth is complemented by a substantial margin beat, which indicates effective cost management and operational efficiency.
Moreover, the integration of iOS with the G6 system has received highly positive feedback, and the upcoming full release of iOS/G7 is expected to further enhance customer satisfaction and drive growth. Under the leadership of the new CEO, Ashley McEvoy, Insulet is poised for continued expansion and profitability. The company’s strategic focus on increasing its scale and leveraging its salesforce to expand its reach, particularly in the Type 2 diabetes segment, underscores its robust growth trajectory.

According to TipRanks, Wood is an analyst with an average return of -1.0% and a 50.00% success rate. Wood covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Insulet, and Baxter International.